A carregar cotações...
Previsão
O preço-alvo médio dos analistas é € 8,66 (+59.215,07%). A mediana é € 8,88 (+60.721,92%).
| Comprar |
4 |
| Manter |
6 |
| Vender |
5 |
Notícias Ir para o feed de notícias
Labcorp raises full-year outlook and focuses on hospital partnerships
Labcorp raised its full-year revenue growth forecast to 7.5–8.6% and expects about 8% growth in its diagnostics business, roughly half organic and half inorganic. The acquisition of Invitae is expected to strengthen the second half and boost the unit’s revenue by about 10%; the deal is seen as slightly accretive. The company targets annual cost savings of USD 100–125 million and anticipates margin improvements, but flags regulatory risks such as possible changes to the ACA/Medicaid and an expected PMM-related charge of around USD 100 million. The focus remains on strategic hospital deals, biopharma services and innovations in women's health, oncology, neurology and autoimmune diseases. » Mais em de.investing.com
Dados financeiros da empresa
| (EUR) | 2022 | YoY |
|---|---|---|
| Receitas | 481,32 mi | 18,87% |
| Ganho bruto | 92,34 mi | 6,07% |
| Ganho líquido | -2,9 bi | 768,85% |
| EBITDA | -2,69 bi | 681,62% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 4,83 mi |
Número de ações | 286,49 mi |
Máximo/mínimo de 52 semanas | € 2,08 - € 0,0133 |
| Dividendos | Não |
Beta | 1,59 |
PER (PE Ratio) | 0,00 |
PEG (PEG Ratio) | 0,00 |
P/VC (PB Ratio) | 0,04 |
P/V (PS Ratio) | 0,01 |
Perfil da empresa
Invitae Corporation, ein Unternehmen für medizinische Genetik, integriert genetische Informationen in die Schulmedizin, um die Gesundheitsversorgung der Menschen in den Vereinigten Staaten, Kanada und international zu verbessern. Das Unternehmen bietet Gentests in verschiedenen klinischen Bereichen an, darunter erblicher Krebs, Kardiologie, Neurologie, Pädiatrie, Onkologie, Stoffwechselkrankheiten und seltene Krankheiten, digitale Gesundheitslösungen und Gesundheitsdatendienste. Das Unternehmen bedient Patienten, Gesundheitsdienstleister, Biopharmaunternehmen und andere Partner. Das Unternehmen war früher als Locus Development, Inc. bekannt und änderte 2012 seinen Namen in Invitae Corporation. Die Invitae Corporation wurde 2010 gegründet und hat ihren Hauptsitz in San Francisco, Kalifornien.
| Nome | Invitae |
| CEO | Kenneth D. Knight |
| Sede | San Francisco,
ca EUA |
| Site | |
| Setor | Cuidados de saúde |
| Indústria | Biotecnologia |
| Entrada em bolsa | 12/02/2015 |
| Colaboradores | 1.700 |
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
London Stock Exchange | 0JDB.L |
NYSE | NVTA |
London | 0JDB.L |
